Urologists' Attitudes Regarding Cancer Clinical Research

Urology

Volumn 70, Issue 1, 2007, Pages 19-24

  Swanson, Gregory P ^a,b   Carpenter, William R ^c   Thompson, Ian M ^a,b   Crawford, E David ^b,d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Southwest Oncology Group   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; CLINICAL PRACTICE; CLINICAL RESEARCH; FEMALE; HUMAN; MALE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; VALIDATION PROCESS;

ATTITUDE OF HEALTH PERSONNEL; BIOMEDICAL RESEARCH; FEMALE; HUMANS; MALE; NEOPLASMS; QUESTIONNAIRES; UROLOGY;

EID: 34447513700     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.03.019     Document Type: Article

References (20)

1. Sateren W.B., Trimble E.L., Abrams J., et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 20 (2002) 2109-2117
2. National Surgical Adjuvant Breast and Bowel Project: NSABP Protocol Chart. (2006), National Surgical Adjuvant Breast and Bowel Project, Pittsburgh
3. Nathan D.G. National Institutes of Health Director's Panel on Clinical Research: Clinical research: perceptions, reality, and proposed solutions. JAMA 280 (1998) 1427-1431
4. U.S. General Accounting Office: NIH Clinical Trials: Various Factors Affect Patient Participation. (1999), U.S. General Accounting Office, Washington, DC
5. Gotay C.C. Accrual to cancer clinical trials: directions from the research literature. Soc Sci Med 33 (1991) 569-577
6. Murthy V.H., Krumholz H.M., and Gross C.P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291 (2004) 2720-2726
7. Ashar B.H., Miller R.G., Getz K.J., et al. Prevalence and determinants of physician participation in conducting pharmaceutical-sponsored clinical trials and lectures. J Gen Intern Med 19 (2004) 1140-1145
8. Taylor K.M., Feldstein M.L., Skeel R.T., et al. Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators. J Clin Oncol 12 (1994) 1796-1805
9. Lloyd T., Phillips B.R., and Aber R.C. Factors that influence doctors' participation in clinical research. Med Educ 38 (2004) 848-851
10. Weinberg A.D., Cooper H.P., Mejia N.I., et al. Attitudes of primary care physicians and specialists about cancer clinical trials: a survey of Texas physicians. Tex Med 100 (2004) 66-72
11. Carpenter W., Weiner B., Kaluzny A., et al. The effects of managed care and competition on community-based clinical research. Med Care 44 (2006) 671-679
12. Norman G., and Streiner D. Biostatistics: The Bare Essentials (1994), Mosby, Baltimore
13. Stata/SE Statistical Software [computer program], version 9.1. College Station, Texas, Stata Press, 2005.
14. O'Leary M.P., Baum N.H., Bohnert W.W., et al. 2003 American Urological Association Gallup survey: physician practice patterns, cryosurgery/brachytherapy, male infertility, female urology and insurance/professional liability. J Urol 171 Pt 1 (2004) 2363-2365
15. Smalley R.V., Murphy S., Huguley Jr. C.M., et al. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res 36 (1976) 3911-3916
16. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352 (1998) 930-942
17. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
18. Okeke A.A., Probert J.L., Gillatt D.A., et al. Is intravesical chemotherapy for superficial bladder cancer still justified?. BJU Int 96 (2005) 763-767
19. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
20. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520